These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 29383798)
1. Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway. Zhang Q; Yang J; Bai J; Ren J Cancer Sci; 2018 Apr; 109(4):944-955. PubMed ID: 29383798 [TBL] [Abstract][Full Text] [Related]
2. The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression. Cho J; Lee HJ; Hwang SJ; Min HY; Kang HN; Park AY; Hyun SY; Sim JY; Lee HJ; Jang HJ; Suh YA; Hong S; Shin YK; Kim HR; Lee HY Cancer Res; 2020 Jun; 80(11):2257-2272. PubMed ID: 32193288 [TBL] [Abstract][Full Text] [Related]
3. Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel. Li SJ; Cao B; Lu ZY; Sun RB; Guo SH; Xie Y; Aa JY; Wang GJ Acta Pharmacol Sin; 2021 Dec; 42(12):2132-2143. PubMed ID: 33658706 [TBL] [Abstract][Full Text] [Related]
4. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function. Zhang S; Wang Y J Biochem Mol Toxicol; 2020 Oct; 34(10):e22560. PubMed ID: 32627280 [TBL] [Abstract][Full Text] [Related]
5. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010 [TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. Tao L; Huang G; Wang R; Pan Y; He Z; Chu X; Song H; Chen L Sci Rep; 2016 Dec; 6():38408. PubMed ID: 27922075 [TBL] [Abstract][Full Text] [Related]
7. mir-1-mediated paracrine effect of cancer-associated fibroblasts on lung cancer cell proliferation and chemoresistance. Li J; Guan J; Long X; Wang Y; Xiang X Oncol Rep; 2016 Jun; 35(6):3523-31. PubMed ID: 27035564 [TBL] [Abstract][Full Text] [Related]
8. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer. Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826 [TBL] [Abstract][Full Text] [Related]
9. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094 [TBL] [Abstract][Full Text] [Related]
10. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Choi DY; You S; Jung JH; Lee JC; Rho JK; Lee KY; Freeman MR; Kim KP; Kim J Proteomics; 2014 Aug; 14(16):1845-56. PubMed ID: 24946052 [TBL] [Abstract][Full Text] [Related]
11. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling. Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515 [TBL] [Abstract][Full Text] [Related]
12. The Nutritional Cytokine Leptin Promotes NSCLC by Activating the PI3K/AKT and MAPK/ERK Pathways in NSCLC Cells in a Paracrine Manner. Li F; Zhao S; Guo T; Li J; Gu C Biomed Res Int; 2019; 2019():2585743. PubMed ID: 31119158 [TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture. Chen S; Giannakou A; Wyman S; Gruzas J; Golas J; Zhong W; Loreth C; Sridharan L; Yamin TT; Damelin M; Geles KG Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11671-E11680. PubMed ID: 30487219 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532 [TBL] [Abstract][Full Text] [Related]
15. [Cancer-associated-fibroblasts regulate the chemoresistance of lung cancer cell line A549 via SDF-1 secretion]. Zou F; Zhang ZH; Zhang YT; Zhao JQ; Zhang XL; Wen CL; Song XY; Zhou WM Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):339-343. PubMed ID: 28535649 [No Abstract] [Full Text] [Related]
16. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer. Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500 [TBL] [Abstract][Full Text] [Related]
17. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway. Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205 [TBL] [Abstract][Full Text] [Related]
18. Suppression of NF-κB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer. Wang LH; Yang JY; Yang SN; Li Y; Ping GF; Hou Y; Cui W; Wang ZZ; Xiao W; Wu CF Curr Cancer Drug Targets; 2014; 14(1):91-103. PubMed ID: 24245692 [TBL] [Abstract][Full Text] [Related]
19. Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer. Song M; Ping Y; Zhang K; Yang L; Li F; Zhang C; Cheng S; Yue D; Maimela NR; Qu J; Liu S; Sun T; Li Z; Xia J; Zhang B; Wang L; Zhang Y Cancer Res; 2019 Jul; 79(14):3737-3748. PubMed ID: 31085700 [TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway. Li B; Yuan Z; Jiang J; Rao Y Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30420490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]